Low-dose aspirin tied to 70% lower dementia risk in certain genetic group

A Monash University analysis of genetic data from over 13,500 participants in the ASPREE trial found that older adults with a specific genetic profile linked to platelet count had a 70 percent lower relative risk of dementia when taking low-dose aspirin. The benefit was not seen across all participants, but researchers say genetic testing could one day guide preventive treatment.